Director/PDMR Shareholding

RNS Number : 7621M

GlaxoSmithKline PLC

17 October 2016

 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sir Andrew Witty
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 370.567 (personal contribution) £17.00 370.555 (personal contribution) £17.00 185.720 (personal contribution £17.00 185.720 (personal contribution) £17.00 465.257 (personal contribution) £17.00 370.567 (matching shares) £17.00 370.555 (matching shares) £17.00 185.720 (matching shares) £17.00 185.720(matching shares) £17.00 465.257 (matching shares)
d)	Aggregated information Aggregated volume Price	3155.638 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	CEO Designate
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 81.138 (personal contribution) £17.00 81.138 (personal contribution) £17.00 64.694 (personal contribution) £17.00 64.694 (personal contribution) £17.00 160.210 (personal contribution) £17.00 160.199 (personal contribution) £17.00 81.138 (matching shares) £17.00 81.138 (matching shares) £17.00 64.694 (matching shares) £17.00 64.694 (matching shares) £17.00 160.210 (matching shares) £17.00 160.199 (matching shares)
d)	Aggregated information Aggregated volume Price	1224.146 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R G Connor
b)	Position/status	President, Global Manufacturing & Supply
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 72.533 (personal contribution) £17.00 72.521 (personal contribution) £17.00 47.378 (personal contribution) £17.00 47.378 (personal contribution) £17.00 108.850 (personal contribution) £17.00 72.533 (matching shares) £17.00 72.521 (matching shares) £17.00 47.378 (matching shares) £17.00 47.378 (matching shares) £17.00 108.850 (matching shares)
d)	Aggregated information Aggregated volume Price	697.320 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 175.105 (personal contribution) £17.00 70.032 (personal contribution) £17.00 90.364 (personal contribution) £17.00 90.352 (personal contribution) £17.00 211.571 (personal contribution) £17.00 211.560 (personal contribution) £17.00 175.105 (matching shares) £17.00 70.032 (matching shares) £17.00 90.364 (matching shares) £17.00 90.352 (matching shares) £17.00 211.571 (matching shares) £17.00 211.560 (matching shares)
d)	Aggregated information Aggregated volume Price	1697.968 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics & Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 33.172 (personal contribution) £17.00 33.172 (personal contribution) £17.00 78.227 (personal contribution) £17.00 78.227 (personal contribution) £17.00 33.172 (matching shares) £17.00 33.172 (matching shares) £17.00 78.227 (matching shares) £17.00 78.227 (matching shares)
d)	Aggregated information Aggregated volume Price	445.596 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S A Hussain
b)	Position/status	President, Global Pharmaceuticals
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 106.388 (personal contribution) £17.00 156.376 (personal contribution) £17.00 184.855 (personal contribution) £17.00 184.855 (personal contribution) £17.00 106.388(matching shares) £17.00 156.376 (matching shares) £17.00 184.855 (matching shares) £17.00 184.855 (matching shares)
d)	Aggregated information Aggregated volume Price	1264.948 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 66.155 (personal contribution) £17.00 66.142 (personal contribution) £17.00 53.158 (personal contribution) £17.00 53.158 (personal contribution) £17.00 99.557 (personal contribution) £17.00 99.557 (personal contribution) £17.00 66.155 (matching shares) £17.00 66.142 (matching shares) £17.00 53.158 (matching shares) £17.00 53.158 (matching shares) £17.00 99.557 (matching shares) £17.00 99.557 (matching shares)
d)	Aggregated information Aggregated volume Price	875.454 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr M M Slaoui
b)	Position/status	Chairman, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $42.39 115.213 (personal contribution) $42.39 115.202 (personal contribution) $42.39 71.742 (personal contribution) $42.39 71.742 (personal contribution) $42.39 118.095 (personal contribution) $42.39 118.095 (personal contribution) $42.39 115.213 (matching shares) $42.39 115.202 (matching shares) $42.39 71.742 (matching shares) $42.39 71.742 (matching shares) $42.39 118.095 (matching shares) $42.39 118.095 (matching shares)
d)	Aggregated information Aggregated volume Price	1220.178 $42.39
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 82.083 (personal contribution) £17.00 71.552 (personal contribution) £17.00 71.540 (personal contribution) £17.00 145.649 (personal contribution) £17.00 145.649 (personal contribution) £17.00 82.083 (matching shares) £17.00 71.552 (matching shares) £17.00 71.540 (matching shares) £17.00 145.649 (matching shares) £17.00 145.649 (matching shares)
d)	Aggregated information Aggregated volume Price	1032.946 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P C Thomson
b)	Position/status	SVP, Communications & Government Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 49.436 (personal contribution) £17.00 48.598 (personal contribution) £17.00 89.112 (personal contribution) £17.00 49.436 (matching shares) £17.00 48.598 (matching shares) £17.00 89.112 (matching shares)
d)	Aggregated information Aggregated volume Price	374.292 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D E Troy
b)	Position/status	SVP & General Counsel
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $42.39 46.628 (personal contribution) $42.39 46.628 (personal contribution) $42.39 37.123 (personal contribution) $42.39 37.123 (personal contribution) $42.39 83.585 (personal contribution) $42.39 83.585 (personal contribution) $42.39 46.628 (matching shares) $42.39 46.628  (matching shares) $42.39 37.123  (matching shares) $42.39 37.123  (matching shares) $42.39 83.585  (matching shares) $42.39 83.585  (matching shares)
d)	Aggregated information Aggregated volume Price	669.344 $42.39
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr P J T Vallance
b)	Position/status	President, Pharmaceuticals R&D
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.00 146.682 (personal contribution) £17.00 146.671 (personal contribution) £17.00 105.324 (personal contribution) £17.00 105.324 (personal contribution) £17.00 171.329 (personal contribution) £17.00 171.329 (personal contribution) £17.00 146.682 (matching shares) £17.00 146.671  (matching shares) £17.00 105.324 (matching shares) £17.00 105.324 (matching shares) £17.00 171.329 (matching shares) £17.00 171.329 (matching shares)
d)	Aggregated information Aggregated volume Price	1693.318 £17.00
e)	Date of the transaction	2016-10-13
f)	Place of the transaction	n/a

 

END

 

 

DSHKDLFFQBFBFBF